Molecular mechanisms of drug resistance in renal cancer;Molekularne mechanizmy chemooporności w raku nerki

Wspolczesna Onkologia

Volumn 9, Issue 3, 2005, Pages 123-128

  Szenajch, Jolanta ^a   Cieślak, Agata ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Cytochrome P450; Multidrug resistance; Oncogenes; P glycoprotein; Renal cancer; Topoisomerase II

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOCHROME P450; DACTINOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; GLUTATHIONE; GLYCOPROTEIN P; IFOSFAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 6; PACLITAXEL; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN C JUN; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR AP 1; VINBLASTINE; VINCA ALKALOID;

ACTIVE TRANSPORT; ARTICLE; CANCER CELL; CANCER RESISTANCE; DRUG RESPONSE; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY TUBULE EPITHELIUM; MULTIDRUG RESISTANCE; SYSTEMIC THERAPY;

EID: 18344376365     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hartmann JT, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 1999; 19: 1541-4.
2. Amato RJ. Chemotherapy for renal cell carcinoma. Sem Oncol 2000; 27: 177-86.
3. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature 2002; 2: 48-58.
4. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11: 1156-66.
5. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmalogical aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-98.
6. Fojo AT, Shen D-W, Mickley LA, Pastan I, Gottesman MM. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987; 5: 1922-7.
7. Schaub TP, Kartenbeck J, Konig J i wsp. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 1999; 10: 1159-69.
8. Belinsky MG, Kruh GD. MOAT-E (ARA) is a full lenght MRR-cMOAT subfamily transporter expressed in kidney and liver. Br J Cancer 1999; 80: 1342-9.
9. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-9.
10. Fromm MA. Genetically determined differences in P-glycoprotein function: implication for disease risk. Toxicology 2002; 181-182: 299-303.
11. Murray RK. Metabolizm ksenobiotyków. W: Murray RK, Granner DK, Mayes PA, Rodwell VW. Biochemia Harpera. Kokot F, Koj A (red.). PZWL, Warszawa 2004; 938-42.
12. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, Melvin WT. Tumor specific expression of cytochrome P450 CYP1B1. Cancer Res 1997; 57: 3026-31.
13. Murray GI, McFadyen MC, Mitchell RT, Cheung Y-L, Kerr AC, Melvin WT. Cytochrome P450 CYP3A in human renal cancer. Br J Cancer 1999; 79: 1836-42.
14. van Brussel, Mickisch GHJ. Circumvention of multidrug resistance in genitourinary tumors. Int J Urol 1998; 5: 1-15.
15. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-79.
16. Mickisch GH, Roehrich K, Koessing J, Forster S, Tschada RK, Alken PM. Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J Urol 1990; 144: 755-9.
17. Ahn H, Lee E, Kim K, Lee C. Effects of glutathione and its related enzymes on chemosensitvity of renal cell carcinoma and bladder carcinoma cell lines. J Urol 1994; 151: 263-7.
18. Stewart CF, Ratain MJ. Pharmacology of cancer chemotherapy. Topoisomerase interactive agents. In: Cancer: Principles and Practice in Oncology. DeVita VF, Hellmann S, Rosenberg SA (red). Lippicott Williams & Wilkins, Philadelphia 2001; 415-8.
19. Scheltema JMW, Romijn JC, van Steenbrugge GJ, Beck WT, Schroder FH, Mickisch GH. Decreased levels of topoisomerse II? in human renal cell carcinoma lines resistant to etoposide. J Cancer Res Clin Oncol 1997; 123: 546-54.
20. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Sci USA 2003, 100: 776-81.
21. Volm M, Kastel M, Mattern MD, Efferth T. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-π, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 1993; 71: 3981-7.
22. Stumm G, Eberwein S, Rostocks-Wolf S, Stein H, Pomer S, Schlegel J, Waldherr R. Concomitant overexpression of the EGFR and erb-B2 in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer 1996; 69: 17-22.
23. Tomita Y, Bilim V, Kawasaki T, Okan I, Magnusson KP, Wiman KG. Frequent expression of Bcl-2 in renal cell carcinomas carrying wild-type p53. Int J Cancer 1996; 66: 322-5.
24. Seima T, Miyagawa I. Expression of Bcl-2, p53 Oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma. Eur Urol 1999; 35: 242-8.
25. Hockenebery DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer SJ. Bcl-2 function in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-51.
26. Mayes PA. Utlenianie biologiczne. W: Murray RK, Granner DK, Mayes PA, Rodwell VW. Biochemia Harpera. Kokot F, Koj A (red.) PZWL, Warszawa 2004; 171.